nodes	percent_of_prediction	percent_of_DWPC	metapath
Labetalol—ADRB3—polycystic ovary syndrome	0.613	0.724	CbGaD
Labetalol—ADRB2—polycystic ovary syndrome	0.233	0.275	CbGaD
Labetalol—Respiratory distress—Metformin—polycystic ovary syndrome	0.00203	0.0749	CcSEcCtD
Labetalol—Nasal congestion—Metformin—polycystic ovary syndrome	0.00103	0.0379	CcSEcCtD
Labetalol—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00096	0.0354	CcSEcCtD
Labetalol—Lethargy—Metformin—polycystic ovary syndrome	0.000956	0.0353	CcSEcCtD
Labetalol—Mirabegron—ADRB3—polycystic ovary syndrome	0.000944	0.136	CrCbGaD
Labetalol—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.000865	0.0319	CcSEcCtD
Labetalol—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.000855	0.0316	CcSEcCtD
Labetalol—Cramp muscle—Metformin—polycystic ovary syndrome	0.000843	0.0311	CcSEcCtD
Labetalol—Fenoterol—ADRB3—polycystic ovary syndrome	0.000831	0.12	CrCbGaD
Labetalol—Angina pectoris—Metformin—polycystic ovary syndrome	0.000788	0.0291	CcSEcCtD
Labetalol—Sweating increased—Metformin—polycystic ovary syndrome	0.000788	0.0291	CcSEcCtD
Labetalol—Arbutamine—ADRB3—polycystic ovary syndrome	0.000777	0.112	CrCbGaD
Labetalol—Drowsiness—Metformin—polycystic ovary syndrome	0.000722	0.0266	CcSEcCtD
Labetalol—Bradycardia—Metformin—polycystic ovary syndrome	0.00066	0.0243	CcSEcCtD
Labetalol—Lisdexamfetamine—ADRA1B—polycystic ovary syndrome	0.000658	0.0949	CrCbGaD
Labetalol—Hepatitis—Metformin—polycystic ovary syndrome	0.000648	0.0239	CcSEcCtD
Labetalol—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000645	0.0238	CcSEcCtD
Labetalol—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000638	0.0236	CcSEcCtD
Labetalol—Flushing—Metformin—polycystic ovary syndrome	0.000601	0.0222	CcSEcCtD
Labetalol—Erythema—Metformin—polycystic ovary syndrome	0.000564	0.0208	CcSEcCtD
Labetalol—Muscle spasms—Metformin—polycystic ovary syndrome	0.000542	0.02	CcSEcCtD
Labetalol—Vision blurred—Metformin—polycystic ovary syndrome	0.000532	0.0196	CcSEcCtD
Labetalol—Tremor—Metformin—polycystic ovary syndrome	0.000528	0.0195	CcSEcCtD
Labetalol—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000523	0.0193	CcSEcCtD
Labetalol—Malaise—Metformin—polycystic ovary syndrome	0.000509	0.0188	CcSEcCtD
Labetalol—Syncope—Metformin—polycystic ovary syndrome	0.000506	0.0187	CcSEcCtD
Labetalol—Palpitations—Metformin—polycystic ovary syndrome	0.000498	0.0184	CcSEcCtD
Labetalol—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000496	0.0183	CcSEcCtD
Labetalol—Hypertension—Metformin—polycystic ovary syndrome	0.000487	0.018	CcSEcCtD
Labetalol—Discomfort—Metformin—polycystic ovary syndrome	0.000474	0.0175	CcSEcCtD
Labetalol—Oedema—Metformin—polycystic ovary syndrome	0.00046	0.017	CcSEcCtD
Labetalol—Shock—Metformin—polycystic ovary syndrome	0.000453	0.0167	CcSEcCtD
Labetalol—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000445	0.0164	CcSEcCtD
Labetalol—Hypotension—Metformin—polycystic ovary syndrome	0.00043	0.0159	CcSEcCtD
Labetalol—Paraesthesia—Metformin—polycystic ovary syndrome	0.000413	0.0153	CcSEcCtD
Labetalol—Dyspnoea—Metformin—polycystic ovary syndrome	0.00041	0.0151	CcSEcCtD
Labetalol—Somnolence—Metformin—polycystic ovary syndrome	0.000409	0.0151	CcSEcCtD
Labetalol—Isoprenaline—ADRB3—polycystic ovary syndrome	0.000406	0.0585	CrCbGaD
Labetalol—Dyspepsia—Metformin—polycystic ovary syndrome	0.000405	0.015	CcSEcCtD
Labetalol—Fatigue—Metformin—polycystic ovary syndrome	0.000397	0.0146	CcSEcCtD
Labetalol—Constipation—Metformin—polycystic ovary syndrome	0.000394	0.0145	CcSEcCtD
Labetalol—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000379	0.014	CcSEcCtD
Labetalol—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000376	0.0139	CcSEcCtD
Labetalol—Urticaria—Metformin—polycystic ovary syndrome	0.000366	0.0135	CcSEcCtD
Labetalol—Abdominal pain—Metformin—polycystic ovary syndrome	0.000364	0.0134	CcSEcCtD
Labetalol—Benazepril—MTHFR—polycystic ovary syndrome	0.000338	0.0488	CrCbGaD
Labetalol—Asthenia—Metformin—polycystic ovary syndrome	0.00033	0.0122	CcSEcCtD
Labetalol—Salmeterol—ADRB2—polycystic ovary syndrome	0.000328	0.0473	CrCbGaD
Labetalol—Pruritus—Metformin—polycystic ovary syndrome	0.000326	0.012	CcSEcCtD
Labetalol—Quinapril—ACE—polycystic ovary syndrome	0.000317	0.0457	CrCbGaD
Labetalol—Ritodrine—ADRB2—polycystic ovary syndrome	0.000316	0.0456	CrCbGaD
Labetalol—Fenoterol—ADRB2—polycystic ovary syndrome	0.000316	0.0456	CrCbGaD
Labetalol—Diarrhoea—Metformin—polycystic ovary syndrome	0.000315	0.0116	CcSEcCtD
Labetalol—Dizziness—Metformin—polycystic ovary syndrome	0.000304	0.0112	CcSEcCtD
Labetalol—Arbutamine—ADRB2—polycystic ovary syndrome	0.000296	0.0426	CrCbGaD
Labetalol—Vomiting—Metformin—polycystic ovary syndrome	0.000293	0.0108	CcSEcCtD
Labetalol—Rash—Metformin—polycystic ovary syndrome	0.00029	0.0107	CcSEcCtD
Labetalol—Dermatitis—Metformin—polycystic ovary syndrome	0.00029	0.0107	CcSEcCtD
Labetalol—Headache—Metformin—polycystic ovary syndrome	0.000288	0.0106	CcSEcCtD
Labetalol—Formoterol—ADRB2—polycystic ovary syndrome	0.000287	0.0414	CrCbGaD
Labetalol—Arformoterol—ADRB2—polycystic ovary syndrome	0.000287	0.0414	CrCbGaD
Labetalol—Benazepril—ACE—polycystic ovary syndrome	0.000276	0.0398	CrCbGaD
Labetalol—Nausea—Metformin—polycystic ovary syndrome	0.000273	0.0101	CcSEcCtD
Labetalol—Dobutamine—ADRB2—polycystic ovary syndrome	0.000272	0.0392	CrCbGaD
Labetalol—Isoprenaline—ADRB2—polycystic ovary syndrome	0.000154	0.0223	CrCbGaD
Labetalol—Isoprenaline—CYP1A1—polycystic ovary syndrome	0.000132	0.0191	CrCbGaD
Labetalol—ADRB3—Signaling Pathways—ADRA1D—polycystic ovary syndrome	7.03e-05	0.00059	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	6.93e-05	0.000581	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	6.91e-05	0.00058	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	6.89e-05	0.000577	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	6.87e-05	0.000576	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ADRA1B—polycystic ovary syndrome	6.84e-05	0.000574	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	6.74e-05	0.000565	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	6.72e-05	0.000564	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—INHBB—polycystic ovary syndrome	6.67e-05	0.000559	CbGpPWpGaD
Labetalol—CYP2D6—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	6.44e-05	0.00054	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—GHRL—polycystic ovary syndrome	6.37e-05	0.000535	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FLT4—polycystic ovary syndrome	6.3e-05	0.000528	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	6.27e-05	0.000526	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	6.25e-05	0.000524	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—GHRL—polycystic ovary syndrome	6.24e-05	0.000523	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PDE3B—polycystic ovary syndrome	6.22e-05	0.000522	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FLT4—polycystic ovary syndrome	6.16e-05	0.000517	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—FSHR—polycystic ovary syndrome	6.14e-05	0.000515	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PDE3B—polycystic ovary syndrome	6.12e-05	0.000513	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—GHRL—polycystic ovary syndrome	6.07e-05	0.000509	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	5.74e-05	0.000481	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—FSHR—polycystic ovary syndrome	5.7e-05	0.000478	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—CYP19A1—polycystic ovary syndrome	5.69e-05	0.000477	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—FSHR—polycystic ovary syndrome	5.67e-05	0.000475	CbGpPWpGaD
Labetalol—CYP2D6—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	5.62e-05	0.000471	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	5.61e-05	0.000471	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—FSHR—polycystic ovary syndrome	5.57e-05	0.000467	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—POMC—polycystic ovary syndrome	5.55e-05	0.000465	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	5.52e-05	0.000463	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—GHRL—polycystic ovary syndrome	5.51e-05	0.000462	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NPB—polycystic ovary syndrome	5.51e-05	0.000462	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—LHB—polycystic ovary syndrome	5.46e-05	0.000458	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	5.4e-05	0.000453	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NPB—polycystic ovary syndrome	5.39e-05	0.000452	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—LHB—polycystic ovary syndrome	5.34e-05	0.000448	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	5.33e-05	0.000447	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—RACGAP1—polycystic ovary syndrome	5.33e-05	0.000447	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	5.28e-05	0.000442	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	5.22e-05	0.000437	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	5.21e-05	0.000437	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ADRA1A—polycystic ovary syndrome	5.19e-05	0.000435	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—SCT—polycystic ovary syndrome	5.11e-05	0.000429	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	5.1e-05	0.000427	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—FST—polycystic ovary syndrome	5.05e-05	0.000424	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	5.02e-05	0.000421	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	5.01e-05	0.000421	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—SCT—polycystic ovary syndrome	5e-05	0.000419	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	4.98e-05	0.000418	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—LHB—polycystic ovary syndrome	4.96e-05	0.000416	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—LHB—polycystic ovary syndrome	4.93e-05	0.000414	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—ADRB3—polycystic ovary syndrome	4.91e-05	0.000411	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—GNAS—polycystic ovary syndrome	4.89e-05	0.00041	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	4.88e-05	0.000409	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	4.87e-05	0.000409	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—LHB—polycystic ovary syndrome	4.85e-05	0.000406	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	4.84e-05	0.000406	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—GNRH1—polycystic ovary syndrome	4.82e-05	0.000404	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—GNAS—polycystic ovary syndrome	4.79e-05	0.000401	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	4.77e-05	0.0004	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—GNRH1—polycystic ovary syndrome	4.74e-05	0.000397	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—AKR1C1—polycystic ovary syndrome	4.67e-05	0.000391	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—GNAS—polycystic ovary syndrome	4.66e-05	0.000391	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—SCT—polycystic ovary syndrome	4.64e-05	0.000389	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SCT—polycystic ovary syndrome	4.62e-05	0.000388	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—LHCGR—polycystic ovary syndrome	4.6e-05	0.000385	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PTGER3—polycystic ovary syndrome	4.6e-05	0.000385	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—CYP1A1—polycystic ovary syndrome	4.59e-05	0.000385	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—ADRB2—polycystic ovary syndrome	4.56e-05	0.000383	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—SCT—polycystic ovary syndrome	4.54e-05	0.000381	CbGpPWpGaD
Labetalol—CYP2D6—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	4.53e-05	0.00038	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—LHCGR—polycystic ovary syndrome	4.5e-05	0.000377	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PTGER3—polycystic ovary syndrome	4.5e-05	0.000377	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	4.43e-05	0.000371	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MTNR1B—polycystic ovary syndrome	4.41e-05	0.00037	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	4.33e-05	0.000363	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—FGF18—polycystic ovary syndrome	4.33e-05	0.000363	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	4.33e-05	0.000363	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PTAFR—polycystic ovary syndrome	4.3e-05	0.000361	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—RBP4—polycystic ovary syndrome	4.3e-05	0.00036	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	4.23e-05	0.000355	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—GNAS—polycystic ovary syndrome	4.23e-05	0.000355	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PTAFR—polycystic ovary syndrome	4.21e-05	0.000353	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	4.17e-05	0.00035	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	4.08e-05	0.000342	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	4.06e-05	0.000341	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NMNAT3—polycystic ovary syndrome	4.04e-05	0.000338	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—YAP1—polycystic ovary syndrome	4.01e-05	0.000336	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	3.97e-05	0.000333	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—INHBB—polycystic ovary syndrome	3.96e-05	0.000332	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—GAB1—polycystic ovary syndrome	3.96e-05	0.000332	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—INHBB—polycystic ovary syndrome	3.87e-05	0.000325	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—INSR—polycystic ovary syndrome	3.78e-05	0.000317	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PDE3B—polycystic ovary syndrome	3.69e-05	0.00031	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—LPCAT2—polycystic ovary syndrome	3.69e-05	0.00031	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SUOX—polycystic ovary syndrome	3.69e-05	0.00031	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PDE3B—polycystic ovary syndrome	3.61e-05	0.000303	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	3.6e-05	0.000302	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—AKR1C3—polycystic ovary syndrome	3.59e-05	0.000301	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TNRC6B—polycystic ovary syndrome	3.54e-05	0.000297	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	3.52e-05	0.000296	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PGR—polycystic ovary syndrome	3.5e-05	0.000294	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ISYNA1—polycystic ovary syndrome	3.43e-05	0.000288	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—POMC—polycystic ovary syndrome	3.42e-05	0.000287	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FSHR—polycystic ovary syndrome	3.36e-05	0.000282	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—POMC—polycystic ovary syndrome	3.29e-05	0.000276	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FSHR—polycystic ovary syndrome	3.29e-05	0.000276	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—GHRL—polycystic ovary syndrome	3.27e-05	0.000274	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—GHRL—polycystic ovary syndrome	3.26e-05	0.000273	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PLAT—polycystic ovary syndrome	3.26e-05	0.000273	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—POMC—polycystic ovary syndrome	3.22e-05	0.00027	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—GHRL—polycystic ovary syndrome	3.2e-05	0.000268	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3.16e-05	0.000265	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—POMC—polycystic ovary syndrome	3.14e-05	0.000263	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ATF1—polycystic ovary syndrome	3.11e-05	0.00026	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3.09e-05	0.00026	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	3.08e-05	0.000258	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TCF7L2—polycystic ovary syndrome	3.03e-05	0.000254	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—AKT2—polycystic ovary syndrome	3.02e-05	0.000253	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	3.01e-05	0.000252	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FST—polycystic ovary syndrome	3e-05	0.000251	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	2.98e-05	0.00025	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.96e-05	0.000248	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FST—polycystic ovary syndrome	2.93e-05	0.000246	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—LHB—polycystic ovary syndrome	2.93e-05	0.000245	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	2.92e-05	0.000245	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	2.92e-05	0.000245	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.9e-05	0.000243	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—NGFR—polycystic ovary syndrome	2.87e-05	0.00024	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—LHB—polycystic ovary syndrome	2.86e-05	0.00024	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.86e-05	0.00024	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—POMC—polycystic ovary syndrome	2.85e-05	0.000239	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PRL—polycystic ovary syndrome	2.84e-05	0.000238	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.8e-05	0.000235	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.77e-05	0.000232	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.77e-05	0.000232	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SCT—polycystic ovary syndrome	2.74e-05	0.00023	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.74e-05	0.00023	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.71e-05	0.000227	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.71e-05	0.000227	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.7e-05	0.000227	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.7e-05	0.000226	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SCT—polycystic ovary syndrome	2.68e-05	0.000225	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.62e-05	0.000219	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FGF18—polycystic ovary syndrome	2.57e-05	0.000216	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.56e-05	0.000215	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—RBP4—polycystic ovary syndrome	2.55e-05	0.000214	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FGF18—polycystic ovary syndrome	2.52e-05	0.000211	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.51e-05	0.000211	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—GNAS—polycystic ovary syndrome	2.5e-05	0.00021	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—RBP4—polycystic ovary syndrome	2.49e-05	0.000209	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.46e-05	0.000206	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	2.45e-05	0.000205	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.38e-05	0.0002	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—YAP1—polycystic ovary syndrome	2.38e-05	0.0002	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—GAB1—polycystic ovary syndrome	2.35e-05	0.000197	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—NRG1—polycystic ovary syndrome	2.34e-05	0.000196	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—YAP1—polycystic ovary syndrome	2.33e-05	0.000195	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	2.32e-05	0.000194	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—GAB1—polycystic ovary syndrome	2.3e-05	0.000193	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—INSR—polycystic ovary syndrome	2.25e-05	0.000188	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	2.21e-05	0.000185	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—INSR—polycystic ovary syndrome	2.2e-05	0.000184	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.13e-05	0.000179	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.1e-05	0.000176	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.09e-05	0.000175	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PGR—polycystic ovary syndrome	2.08e-05	0.000174	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.05e-05	0.000172	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PGR—polycystic ovary syndrome	2.03e-05	0.000171	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IRS2—polycystic ovary syndrome	2e-05	0.000168	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	1.97e-05	0.000165	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—LEP—polycystic ovary syndrome	1.96e-05	0.000164	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—GHRL—polycystic ovary syndrome	1.93e-05	0.000162	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PLAT—polycystic ovary syndrome	1.93e-05	0.000162	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PLAT—polycystic ovary syndrome	1.89e-05	0.000159	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—GHRL—polycystic ovary syndrome	1.89e-05	0.000159	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	1.88e-05	0.000158	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.86e-05	0.000156	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ATF1—polycystic ovary syndrome	1.84e-05	0.000155	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.82e-05	0.000153	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ATF1—polycystic ovary syndrome	1.8e-05	0.000151	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.8e-05	0.000151	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.79e-05	0.00015	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.76e-05	0.000147	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.75e-05	0.000147	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IRS1—polycystic ovary syndrome	1.75e-05	0.000147	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	1.71e-05	0.000144	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NGFR—polycystic ovary syndrome	1.7e-05	0.000143	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—POMC—polycystic ovary syndrome	1.69e-05	0.000142	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PRL—polycystic ovary syndrome	1.69e-05	0.000141	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—POMC—polycystic ovary syndrome	1.68e-05	0.000141	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	1.68e-05	0.000141	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—INS—polycystic ovary syndrome	1.67e-05	0.00014	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NGFR—polycystic ovary syndrome	1.66e-05	0.00014	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—POMC—polycystic ovary syndrome	1.65e-05	0.000139	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PRL—polycystic ovary syndrome	1.65e-05	0.000138	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.63e-05	0.000136	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	1.62e-05	0.000136	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IGF1—polycystic ovary syndrome	1.62e-05	0.000136	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—AKT2—polycystic ovary syndrome	1.62e-05	0.000136	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.6e-05	0.000134	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.59e-05	0.000133	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.54e-05	0.000129	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	1.49e-05	0.000125	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—GNAS—polycystic ovary syndrome	1.48e-05	0.000124	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—GNAS—polycystic ovary syndrome	1.45e-05	0.000122	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	1.45e-05	0.000121	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.41e-05	0.000118	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	1.39e-05	0.000117	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.39e-05	0.000116	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.38e-05	0.000116	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.36e-05	0.000114	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	1.34e-05	0.000112	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	1.32e-05	0.000111	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	1.25e-05	0.000105	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—IL6—polycystic ovary syndrome	1.24e-05	0.000104	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	1.23e-05	0.000103	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.19e-05	9.96e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	1.16e-05	9.75e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.16e-05	9.75e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—LEP—polycystic ovary syndrome	1.14e-05	9.54e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—TH—polycystic ovary syndrome	1.06e-05	8.93e-05	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.06e-05	8.87e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.04e-05	8.7e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	1.04e-05	8.68e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.01e-05	8.51e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	9.99e-06	8.37e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	9.93e-06	8.33e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—POMC—polycystic ovary syndrome	9.77e-06	8.19e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	9.74e-06	8.16e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—INS—polycystic ovary syndrome	9.72e-06	8.15e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	9.61e-06	8.06e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	9.6e-06	8.05e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IGF1—polycystic ovary syndrome	9.4e-06	7.88e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—AKT2—polycystic ovary syndrome	9.39e-06	7.87e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.12e-06	7.65e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.92e-06	7.48e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	8.69e-06	7.29e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	8.28e-06	6.94e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	7.85e-06	6.58e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	7.35e-06	6.16e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	7.32e-06	6.14e-05	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IL6—polycystic ovary syndrome	7.31e-06	6.13e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—IL6—polycystic ovary syndrome	7.19e-06	6.03e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.28e-06	5.26e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.14e-06	5.15e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	5.93e-06	4.97e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	5.85e-06	4.91e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—INS—polycystic ovary syndrome	5.82e-06	4.88e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	4.34e-06	3.64e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IL6—polycystic ovary syndrome	4.25e-06	3.56e-05	CbGpPWpGaD
